• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Weekly GLP-1 receptor agonists may reduce HbA1c and fasting glucose

byJeffrey CampbellandSai Folmsbee
December 8, 2015
in Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this systematic review and meta-analysis, the use of weekly glucagon-like peptide-1 receptor agonists (GLP1-RAs) was associated with a significant reduction in fasting glucose and HbA1c when compared to placebo.

2. Of the weekly GLP1-RAs compared, duraglutide, exenatide and taspoglutide were associated with the greatest decrease in fasting glucose and HbA1c, although high dose taspoglutide (20 mg) was associated with increased risk of nausea compared to other GLP1-RAs.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a relatively new type of therapy targeting high blood sugar in patients with type 2 diabetes mellitus (T2DM). Development of weekly GLP1-RAs may reduce side effects and increase adherence to these drugs, all of which can be injected. However, while prior research has compared GLP1-RAs to other diabetes treatments, there have been no comparisons of the efficacy or side effects of different weekly GLP1-RAs. This study used a specialized statistical method—a “network meta-analysis”—to combine results from trails of different GLP1-RAs. Four different GLP1-RA drugs—albiglutide, dulaglutide, exenatide, and taspoglutide—were compared to placebo and to each other to determine relative efficacy and side effects. Overall, all drugs reduced short-term and long-term blood sugar compared to placebo. Three drugs—duraglutide, exenatide, and taspoglutide—resulted in the greatest decreases in short-term and long-term blood sugar markers, as well as body weight. No differences were found between drugs in risk of symptomatic low blood sugar. However, taking taspoglutide at a high dose was associated with increased incidence of nausea compared to taking the other drugs. Notably, several of the trials included in this analysis were sponsored by pharmaceutical companies, raising the possibility of publication bias. Nevertheless, in the absence of trials directly comparing these therapies, this study provides the best evidence to date on the comparative effectiveness of several weekly GLP1-RA drugs. These results may guide clinical decision-making, and set an agenda for comparative clinical trials.

Click to read the study published today in the Annals of Internal Medicine

Relevant Reading: Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

In-Depth [systematic review and network meta-analysis]: This network meta-analysis drew data from 34 randomized controlled trials (21,126 participants) comparing weekly-administered GLP1-RAs to other glucose-lowering drugs or placebo. Use of each drug was associated with significantly decreased HbA1c compared to placebo; mean HbA1c reduction ranged from 1.4% (95%CI 1.6%-1.2%) for dulaglutide 1.5 mg to 0.9% (95%CI 1.2%-0.8%) for taspoglutide 10 mg. In the network meta-analysis, dulaglutide 1.5 mg out-performed all other drugs except for exenatide in terms of HbA1c reduction. All drugs were associated with significant reductions in fasting blood sugar, ranging from decreases of 2.2 mmol/L (95%CI 2.6-1.8mmol/L) for exenatide to 1.5 mmol/L (95%CI 1.9-1.1mmol/L) for albiglutide. In the network meta-analysis, use of exenatide was associated with significantly decreased fasting blood sugar compared to all drugs except high-dose (20 mg) taspoglutide and high-dose (1.5 mg) dulaglutide. All drugs significantly increased risks for nausea compared to placebo, and taspoglutide 20 mg was associated with significantly increased risks of nausea compared to all other drugs.

RELATED REPORTS

Faricimab may improve visual acuity in patients with diabetic macular edema

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetes mellitus
Previous Post

Majority of adolescents’ physical activity obtained at school

Next Post

The RE-ALIGN trial: Dabigatran vs. warfarin for mechanical heart valves [Classics Series]

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Insulin costs rose exponentially, regardless of formulation or patent
Cardiology

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

February 9, 2022
Cardiology

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

January 11, 2022
#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes
StudyGraphics

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

December 2, 2021
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The RE-ALIGN trial: Dabigatran vs. warfarin for mechanical heart valves [Classics Series]

Needlestick injuries most common in first six months of residency

Needlestick injuries most common in first six months of residency

High school cheerleading injury rates lower than other sports

High school cheerleading injury rates lower than other sports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Same appointment mammogram results may result in less stress for patients being screened for breast cancer
  • Increased use of pediatric CT poses significant oncogenic risk [Classics Series]
  • Pediatric asthma morbidity is associated with geographic location and social determinants of health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.